Kadimastem is at the forefront of cell therapy, focusing on innovative regenerative treatments for incurable diseases. The company has developed a unique platform that allows for the production of off-the-shelf cell-based products, addressing significant unmet medical needs. Their lead product, AstroRx®, consists of clinical-grade human astrocytes designed to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Kadimastem has received FDA clearance to initiate a Phase IIa clinical trial in the U.S., following promising results from earlier trials in Israel that demonstrated a good safety profile and a meaningful decline in disease progression among ALS patients.

In addition to AstroRx®, Kadimastem is advancing IsletRx, which comprises clinical-grade pancreatic islet cells that produce insulin and glucagon in response to blood glucose levels. This product utilizes a proprietary micro-encapsulation technology that protects the islet cells from the host immune system, thereby enhancing therapeutic efficacy without the need for immunosuppressive drugs. Kadimastem's approach aims to provide a sustainable solution for insulin-dependent diabetes, particularly Type 1 diabetes, by freeing patients from the burdens of continuous blood sugar monitoring and insulin injections. The company is committed to moving these therapies from pre-clinical stages to human trials, with a focus on scalability and safety in the commercialization of cellular therapeutics.

Israel

Kadimastem (TASE:KDST) A clinical stage biotech company introducing a cutting-edge TECHNOLOGY PLATFORM for the Development, Manufacturing, and Bio-Banking of functional human cells, providing OFF-THE-SHELF TREATMENT for multiple indications featuring ALS and Type 1 Diabetes as our top two leading projects.

Kadimastem

Company Details